NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Novartis
Novartis
Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc.
Hoffmann-La Roche
Novartis
Endeavor Biomedicines, Inc.
Novartis
ViroMissile, Inc.
Eisai Inc.
Exelixis
Ipsen
Merck Sharp & Dohme LLC
Daiichi Sankyo
Hoffmann-La Roche
Boston Scientific Corporation
Corcept Therapeutics